Thank you.
Mr. MacLeod, researchers estimated before this committee and otherwise that overall savings in Canada could be achieved by a national universal pharmacare program in the nature of $4 billion to $11 billion annually, depending on the structure of the system and the parameters adopted.
According to your report, an expert panel I think urged a more conservative view of cost savings achieved through universal pharmacare. Was the reference panel still in favour of a national universal pharmacare program if it achieves universal coverage but results in no overall cost savings to government for pharmaceuticals? Should we proceed anyway?